Discounted Cash Flow Rating

Strong Buy

Return on Equity Rating

Strong Buy

Debt to Equity Rating

Neutral

Price to Earnings Rating

Sell

Analyst Rating

Buy

Alpha Metallurgical Resources, Inc. (AMR)

Bituminous Coal & Lignite Surface Mining

https://www.alphametresources.com

Alpha Metallurgical Resources Inc is a Tennessee-based coal mining company with operations across Virginia and West Virginia. The company's portfolio of mining operations consists of underground mines, surface mines and coal preparation plants. It produces low-ash metallurgical coal, including High-Vol. A, Mid-Vol., High-Vol. B, and Low-Vol. coal, which is shipped to domestic and international coke and steel producers. The reportable segments of the company are Met. It extracts, processes and markets met and thermal coal from deep and surface mines for sale to steel and coke producers, industrial customers, and electric utilities.

340 MARTIN LUTHER KING JR. BLVD.
BRISTOL, TN

Current Price

---.--

% Change Today

0.00%

Change Amt. Today

0.00

Active Status

Active

Listing Date

08/18/2016

Market Cap

3,100,736,600

Shares Outstanding

13,280,000

Weighted SO

13,283,594

Total Employees

N/A

Upcoming Earnings

08/05/2024

Beta

1.3850

Last Div

2.0000

Range

186.74-452.0

Chg

3.0450

Avg Vol

199050

Mkt Cap

3100736600

Exch

NYSE

Country

US

Phone

423 573 0300

DCF Diff

-330.9096

DCF

570.4496

Div Yield

0.0042

P/S

0.9201

EV Multiple

3.8200

P/FV

1.8863

Div Yield %

0.4198

P/E

6.8026

PEG

0.3108

Payout

0.0514

Current Ratio

3.5507

Quick Ratio

2.8320

Cash Ratio

1.0891

DSO

54.7084

DIO

29.6439

Op Cycle

84.3524

DPO

16.3742

CCC

67.9782

Gross Margin

0.1895

Op Margin

0.1611

Pretax Margin

0.1551

Net Margin

0.1352

Eff Tax Rate

0.1281

ROA

0.1828

ROE

0.2863

ROCE

0.2486

NI/EBT

0.8719

EBT/EBIT

0.9625

EBIT/Rev

0.1611

Debt Ratio

0.0034

D/E

0.0052

LT Debt/Cap

0.0032

Total Debt/Cap

0.0052

Int Coverage

162.9757

CF/Debt

83.9568

Equity Multi

1.5168

Rec Turnover

6.6717

Pay Turnover

22.2912

Inv Turnover

12.3128

FA Turnover

3.1362

Asset Turnover

1.3518

OCF/Share

55.2500

FCF/Share

36.7326

Cash/Share

25.8303

OCF/Sales

0.2134

FCF/OCF

0.6648

CF Coverage

83.9568

ST Coverage

220.3512

CapEx Coverage

2.9837

Div&CapEx Cov

2.7192

P/BV

1.8863

P/B

1.8863

P/S

0.9201

P/E

6.8026

P/FCF

6.4865

P/OCF

4.3118

P/CF

4.3118

PEG

0.3108

P/S

0.9201

EV Multiple

3.8200

P/FV

1.8863

DPS

1.0000

Latest Headlines (EST)

GlobeNewswire Inc. May 13, 06:00 2024 Exploration Update for Strategic Minerals JV GlobeNewswire Inc. Jan 22, 07:30 Amarin Chairman & CEO Issue Letter to Shareholders GlobeNewswire Inc. Jan 18, 16:15 Lamar Advertising Announces Tax Reporting Information For 2023 Distributions on Common Stock GlobeNewswire Inc. Jan 17, 16:15 Lamar Advertising Company to Release Fourth Quarter Ended December 31, 2023 Operating Results The Motley Fool Jan 10, 19:02 Why Amarin Stock Skyrocketed Today The Motley Fool Jan 10, 19:02 Why Amarin Stock Skyrocketed Today The Motley Fool Jan 10, 19:02 Why Amarin Stock Skyrocketed Today The Motley Fool Jan 10, 19:02 Why Amarin Stock Skyrocketed Today The Motley Fool Jan 10, 19:02 Why Amarin Stock Skyrocketed Today GlobeNewswire Inc. Jan 05, 16:05 A-Mark Precious Metals Announces Quarterly Cash Dividend GlobeNewswire Inc. Nov 20, 16:30 A-Mark Precious Metals Increases Share Repurchase Program GlobeNewswire Inc. Nov 14, 07:30 AM Resources Makes Changes to Management and Board GlobeNewswire Inc. Nov 12, 09:00 New REDUCE-IT® Analyses Show VASCEPA® (icosapent ethyl) Associated with 29 Percent Relative Risk Reduction Compared with Placebo in Prespecified Subgroup of Patients with Metabolic Syndrome, but Without Diabetes at Baseline GlobeNewswire Inc. Nov 12, 09:00 New REDUCE-IT® Analyses Show VASCEPA® (icosapent ethyl) Associated with 29 Percent Relative Risk Reduction Compared with Placebo in Prespecified Subgroup of Patients with Metabolic Syndrome, but Without Diabetes at Baseline GlobeNewswire Inc. Nov 12, 09:00 New REDUCE-IT® Analyses Show VASCEPA® (icosapent ethyl) Associated with 29 Percent Relative Risk Reduction Compared with Placebo in Prespecified Subgroup of Patients with Metabolic Syndrome, but Without Diabetes at Baseline GlobeNewswire Inc. Nov 12, 09:00 New REDUCE-IT® Analyses Show VASCEPA® (icosapent ethyl) Associated with 29 Percent Relative Risk Reduction Compared with Placebo in Prespecified Subgroup of Patients with Metabolic Syndrome, but Without Diabetes at Baseline GlobeNewswire Inc. Nov 12, 09:00 New REDUCE-IT® Analyses Show VASCEPA® (icosapent ethyl) Associated with 29 Percent Relative Risk Reduction Compared with Placebo in Prespecified Subgroup of Patients with Metabolic Syndrome, but Without Diabetes at Baseline GlobeNewswire Inc. Nov 12, 09:00 New REDUCE-IT® Analyses Show VASCEPA® (icosapent ethyl) Associated with 29 Percent Relative Risk Reduction Compared with Placebo in Prespecified Subgroup of Patients with Metabolic Syndrome, but Without Diabetes at Baseline The Motley Fool Nov 07, 15:51 Why Ameresco Stock Plunged Today The Motley Fool Nov 01, 12:30 Amarin Plc (AMRN) Q3 2023 Earnings Call Transcript

Revenue Product Segmentation

Dividend History

Cash Value Ex-Dividend Date Declaration Date Record Date Pay Date
0.50 11/30/2023 10/31/2023 12/01/2023 12/15/2023
0.50 09/14/2023 08/02/2023 09/15/2023 10/03/2023
0.50 06/14/2023 05/03/2023 06/15/2023 07/05/2023
0.44 03/14/2023 02/21/2023 03/15/2023 04/03/2023
5.42 12/14/2022 11/04/2022 12/15/2022 01/03/2023
0.39 09/14/2022 08/04/2022 09/15/2022 10/03/2022
0.38 06/14/2022 05/05/2022 06/15/2022 07/01/2022